Brief: Icosavax Inc - Ivx-121 Continues To Be Generally Well Tolerated With No Safety Concerns Observed In This Six-Month Follow Up

Icosavax

13/12/2022 21:41

Dec 13 (Reuters) - Icosavax Inc  ICVX.O :
    * ICOSAVAX INC - IVX-121 CONTINUES TO BE GENERALLY WELL
TOLERATED
WITH NO SAFETY CONCERNS OBSERVED IN THIS SIX-MONTH FOLLOW UP
    * ICOSAVAX INC - IN NEW DATA FROM PHASE 1/1B STUDY, IVX-121
SHOWED
SUSTAINED IMMUNOLOGIC RESPONSE AT SIX MONTHS
    * ICOSAVAX INC - IVX-A12 (A BIVALENT OF IVX-121 FOR RSV AND
IVX-241 FOR HMPV) PROGRESSING IN PHASE 1
    * ICOSAVAX INC - ICOSAVAX PLANS TO PROVIDE A 12-MONTH
IMMUNOGENICITY UPDATE FROM AN EXTENSION OF THIS PHASE 1B TRIAL
IN MID-2023
    * ICOSAVAX INC - ALSO INTENDS TO PRESENT ADDITIONAL DATA
FROM ITS
PHASE 1/1B CLINICAL TRIAL OF IVX-121 AT A FUTURE MEDICAL MEETING

Source text for Eikon:  ID:nGNX7MRQc8 
Further company coverage:  ICVX.O 
 ((Reuters.Briefs@thomsonreuters.com;;))